Innate Pharma S.A. (EPA:IPH)

France flag France · Delayed Price · Currency is EUR
1.862
-0.014 (-0.75%)
Mar 28, 2025, 5:35 PM CET
-14.98%
Market Cap 156.06M
Revenue (ttm) 20.12M
Net Income (ttm) -49.47M
Shares Out 83.81M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE 1.39
Dividend n/a
Ex-Dividend Date n/a
Volume 53,498
Average Volume 117,861
Open 1.852
Previous Close 1.876
Day's Range 1.852 - 1.888
52-Week Range 1.332 - 2.790
Beta 0.86
RSI 42.88
Earnings Date Mar 27, 2025

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 179
Stock Exchange Euronext Paris
Ticker Symbol IPH
Full Company Profile

Financial Performance

In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.

Financial Statements

News

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for full year 2024 financial results.

10 days ago - Business Wire

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in The 2025 Leerink Partners Global Healthcare Conference.

4 weeks ago - Business Wire

Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion

Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Resp...

5 weeks ago - Seeking Alpha

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome.

5 weeks ago - Business Wire

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

Shares of Logility Supply Chain Solutions, Inc . (NASDAQ: LGTY) rose sharply in today's pre-market trading after Aptean announced an agreement to acquire Logility in a $14.30-per-share all-cash deal ...

2 months ago - Benzinga

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its P...

2 months ago - Business Wire

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces Nectin-4 antibody drug conjugate investor and analyst event in New York.

2 months ago - Business Wire

Innate Pharma Announces Transformative Strategy to Accelerate Growth

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its updated strategy for company growth. ...

2 months ago - Business Wire

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its management will present and host...

3 months ago - Business Wire

Innate Pharma presents lacutamab improved health-related quality of life data at ASH 2024

New data from Innate Pharma SA highlights quality-of-life improvements in patients with cutaneous T-cell lymphoma treated with lacutamab in the TELLOMAK...

3 months ago - Seeking Alpha

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life...

3 months ago - Business Wire

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

MARSEILLE, France & DIAMOND BAR, Calif.--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), together with the Institute for Fo...

4 months ago - Business Wire

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutamab healt...

4 months ago - Business Wire

Innate Pharma: Looking Like A Company We'll Regret Ignoring

Innate has a stable of interesting pipeline projects in development for a range of cancers. The most advanced candidate is poised for a potential accelerated approval for cutaneous T-cell lymphoma. Ot...

4 months ago - Seeking Alpha

Innate Pharma Releases Its 2025 Financial Calendar

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2025 financial calendar: March 27, 202...

4 months ago - Business Wire

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication in Science Immunology of ...

4 months ago - Business Wire

Innate Pharma reports 9M results

4 months ago - Seeking Alpha

Innate Pharma S.A. 2024 Q3 - Results - Earnings Call Presentation

The following slide deck was published by Innate Pharma S.A.

4 months ago - Seeking Alpha

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results...

4 months ago - Business Wire

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the ...

5 months ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for third quarter 2024 results and business updates.

5 months ago - Business Wire

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conferences.

5 months ago - Business Wire